Provectus Algae Secures Grant to Advance R&D, Global Commercialisation of Innovative Synthetic Biology Stack

Software

TeselaGen Biotechnology Releases New Protein Optimization Toolkit for Automated Biotherapeutic Drug Design and Development

New functionality accelerates the design and development process, reducing R&D costs of biotherapeutics and vaccines SAN FRANCISCO (PRWEB) MAY 20, 2021 TeselaGen Biotechnology today announced the release of a new...

Benchling Launches Support for the Discovery and Development of RNA Therapeutics

TeselaGen Biotechnology Releases New Protein Optimization Toolkit for Automated Biotherapeutic Drug Design and Development

Veteran Technology Executive Joins Synthace to Accelerate its Mission to Revolutionize the Life Science Research Market

Visualizing the Future: Spatialomics Transforms Study of Gene Expression

Benchling Raises $200M Series E To Accelerate Biotech R&D

Riffyn Launches Riffyn Nexus v4.2 to Strengthen Bioprocess Data Integrity With Automated Data Validation

Synthace More Than Doubles Its Annual Recurring Revenue; Expands Customer Footprint With the Top Pharma Companies In 2020

TeselaGen Partners with Berkeley Lab’s Advanced Biofuels and Bioproducts Process Development Unit to Accelerate the Bioeconomy

Three black and white images of pioneering women in science

Meet the Heroes You Never Knew You Had

Riffyn Doubles Customers and Recurring Revenue for Fourth Straight Year

Benchling Doubles Annual Recurring Revenue (ARR) for Fourth Straight Year Amid COVID-19 Pandemic

LanzaTech and TeselaGen Biotechnology Sign New Multi-Year Deal to Advance Carbon Remediation via Biological Processes

Riffyn Selected as the Digital Backbone of BioMADE Network to Advance Domestic Biomanufacturing Innovation

Synthace and Ipsen Partner to Accelerate Novel Therapeutic Development Through Automation